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Background: The effect of sickle cell disease (SCD) on tumor growth is unknown. Sickled red blood cells may form
aggregates within the microvasculature of hypoxic tumors and reduce blood flow leading to impairment of tumor
growth. However, there is a paucity of data related to tumor growth in SCD.
Methods: To investigate the effect of SCD on tumor growth in a melanoma model, we generated SCD and control
mice using bone marrow transplantation and inoculated the chest wall with B16-F10 melanoma cells. Tumor growth
was monitored and angiogenesis was studied in vivo and in vitro.
Results: From day 1 to 21, tumor growth rate was nearly identical between SCD and WT mice, however from day 22
to day 29 tumor growth was accelerated in SCD mice compared to WT mice. Disparity in tumor size was confirmed at
autopsy with an approximate 2-fold increase in tumor weights from SCD mice. Tumors from SCD mice showed
increased vascularity and elevated levels of heme oxygenase-1 (HO-1). HO-1 inhibition with zinc protoporphyrin
(ZnPP) blocked the angiogenic and tumor growth response to SCD in vivo and the response to hemin in vitro.
Conclusions: Growth of melanoma tumors is potentiated in a mouse model of SCD. Therapies targeting
angiogenesis or HO-1 may be useful in SCD patients with malignant tumors.
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Malignant tumors are characterized by regions of hyp-
oxia as the growth and metabolism of the tumor out-
paces the supply of oxygenated blood [1]. These areas of
hypoxia have been shown to induce local sickling of in-
fused red blood cells that carry the mutation for sickle cell
disease (SCD) [2]. Since SCD is associated with elevated
heme oxygenase-1 (HO-1) due to chronic hemolysis [3],
SCD may promote tumor growth. HO-1 overexpression
has been previously shown to promote the growth of some
tumors, including melanoma [4]. SCD has also been
shown to promote angiogenic responses [5], which could
promote tumor growth [6].
To our knowledge, the effect of host SCD on tumor
growth has not been previously reported. Because of the
potential of SCD to modify the growth of malignant* Correspondence: deitzman@umich.edu
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tumors in a mouse model of SCD.Materials and methods
Ethics statement
All procedures complied with the Principles of Laboratory
and Animal Care established by the National Society for
Medical Research and were approved by the University of
Michigan Committee on Use and Care of Animals.Mice
Wild-type C57BL6/J male mice were purchased from
the Jackson Laboratory (Bar Harbor, ME). Male 8 week
old mice were fed a standard laboratory rodent diet
(#5001, TestDiet, Richmond, Ind) in specific pathogen-
free facilities. Donor mice carrying the homozygous
sickle cell mutation (Hbbhβs/hβs) were originally from
University of Alabama at Birmingham [7] and these mice
have subsequently been bred to C57BL6/J mice to gener-
ate heterozygous mice, which were then intercrossed toicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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control experimental mice were then generated by bone
marrow transplantation (BMT) from Hbbhβs/hβs mice or
wild-type (Hbb+/+) donors to wild-type C57BL6/J male re-
cipients. All procedures complied with the Principles of
Laboratory and Animal Care established by the National
Society for Medical Research and were approved by the
University of Michigan Committee on Use and Care of
Animals.
Cell culture
Murine melanoma (B16-F10, CRL-6475™, ATCC) and
brain endothelial cells (bEnd.3, CRL-2299™, ATCC) were
grown in Dulbecco’s modified Eagle medium (DMEM,
Gibco Inc.) containing 10 % fetal bovine serum (FBS,
Gibco Inc.) and passaged 2 to 3 times before use in assays.
Bone marrow transplantation
Male donor mice for BMT were euthanized at 8–10
weeks of age and bone marrow was then flushed from
femurs and tibias. Recipient mice were irradiated with
650 rads x 2 separated by a 3 hour interval (total of
1300 rads). Each recipient mouse was administered a
200 μl bone marrow suspension in PBS (2 × 107cells/ml)
via tail vein injection. Acid water (6 mM HCL, pH = 2.5)
was provided to animals beginning 4 days before BMT
to 4 weeks following BMT. Recipient mice were housed
in a specific pathogen free animal facility.
Tumor model
Melanoma tumors were induced by subcutaneous injec-
tion of 1 × 105 B16-F10 murine melanoma cells over the
left lateral chest wall. This melanoma cell line is from
the same strain background as the recipient mice, thus it
is not rejected. Tumor size and body weight were mea-
sured daily for four weeks. Tumor volumes were calcu-
lated using the formula 0.5 x length x width2 [9].
HO-1 activity assay
The enzyme activity of HO-1 was measured as previ-
ously described [3]. Briefly, 100 mg frozen tumor tissue
was homogenized in 250 μl PBS, and centrifuged at
18,000 g for 10 min at 4 ° C. The source of biliverdin re-
ductase for each assay was prepared by centrifuging 2 mg
WT homogenized liver. To initiate the reaction, 200 μl
supernatant of tumor sample was added to a reaction sys-
tem containing 0.8 mmol/L NADPH, 2 mmol/L glucose-
6-phosphate, 0.2 units glucose-6-phosphate dehydrogen-
ase, 0.2 mmol/L MgCl2, 0.02 mmol/L hemin, and 100 μl
liver cytosol in a final volume of 300 μl. The reaction mix-
ture was incubated for 60 min at 37 ° C in the dark and
then stopped by mixing 1:1 with chloroform. The ex-
tracted bilirubin in the chloroform was measured at 464
nm subtracted by absorption at 530 nm. The HO activitywas expressed as formation of bilirubin (pmol) per milli-
gram of sample in 1 h. Units of activity are therefore
pmol/mg/hr.
HO-1 inhibition
The HO-1 inhibitor, zinc protoporphyrin IX (ZnPP,
Sigma, St. Louis, MO, USA), was prepared in 0.1 N
NaOH, and then titrated to pH 7.4 using 0.1 N HCl.
ZnPP (2.5 mg/kg in 0.9 % NaCl) was given IP twice a
week to tumor- bearing mice. For aortic ring assays,
ZnPP was added at 2.5 μM.
Tumor angiogenesis
At the end of the protocol, mice were euthanized and
perfused with PBS. Tumors were fixed with formalin,
paraffin-embedded and sectioned (5μm). Endothelial
cells were stained with an anti-mouse CD31 monoclonal
antibody (1:50, Abcam, Cambridge, MA). For quantita-
tion of vessel density, the areas of highest neovasculari-
zation, “hot spots”, were identified by scanning the
sections at low power (200X) followed by vessel counts
at high power (400X), as previously described [10]. For
each tumor section, five hot spots were identified and
vessels were counted.
RT-PCR
For HO-1 expression analyses, bEnd.3 cells were seeded
in 6-well plates (Cat #3516, Corning Inc.) and allowed to
form a confluent monolayer. DMSO or hemin at varying
concentrations (three wells per concentration) were
added to the medium for 5 hours before cells were har-
vested. RNA was isolated using a QIAGEN RNeasy Mini
Kit (QIAGEN Inc., Valencia, CA) according to manufac-
turer’s instructions. Primer sets for specific amplification
of murine HO-1 and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) were purchased from Applied
Biosystems (Carlsbad, CA). RT-PCR was performed
using an ABI Prism 7000 Sequence Detection System
(Applied Biosystems), with 200 ng RNA and 1 μL primer
used per reaction. Results were analyzed using 7000 Sys-
tem SDS Software and the 2-ΔΔCT method [11]. HO-1
expression levels were presented as percentage of DMSO
control.
Aortic ring angiogenesis assay
For analysis of aortic ring angiogenesis, 150 μl Cultrex
BME (R&D Systems, 3432-005-01) was added to each
well of a 48-well plate and placed in an incubator for 30
minutes to solidify the matrix. WT BMT mice were eu-
thanized, thoracotomy was performed and thoracic aorta
was removed. Aortas were cleaned of adventitial tissue
and blood and then serially cross-sectioned into 1–2
mm rings. For each group, four aortic rings were embed-
ded in 300 μl Cultrex BME (R&D Systems, 3432-005-01)
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control or hemin (with or without ZnPP) was added and
the rings were cultured for 7 days with 2 media changes.
Images were taken and the number of sprouts was
counted [12].
Matrigel plug assay
For matrigel experiments, growth factor-reduced matri-
gel (300 μl; 3432-005-01, BD Bioscience) was injected
subcutaneously into the ventral aspect of each mouse.
WT mice treated with PBS (n = 3) or ZnPP (n = 5) and
SCD mice treated with PBS (n = 5) or ZnPP (n = 5) were
studied. 10 days after implantation, mice were eutha-
nized and plugs were removed, fixed with formalin, em-
bedded with paraffin, sectioned, and stained with anti-
CD31 antibody. The vascular density was determined by
counting number of blood vessels per matrigel plug sec-
tion [13].
Statistical analysis
Values are expressed as mean ± SD. The statistical sig-
nificance of differences between two groups was deter-
mined by the student 2-tailed t test. For multiple
comparisons, results were analyzed using two-way
ANOVA, followed by Bonferroni post-test analysis. P <
0.05 was considered significant. For analysis of mice withFig. 1 Accelerated tumor growth in SCD mice. a Growth curves of WT mic
bearing SCD and WT mouse at time of sacrifice. c Tumor weights of WT an
vessels from SCD mice. Scale bar = 25 μmmetastasis, Fisher’s exact test was used. Pearson correl-
ation test was performed for correlation analyses.Results
Effect of SCD on melanoma growth rate
To determine the effect of SCD on the growth of malig-
nant tumors, we implanted murine melanoma cells in
SCD and WT recipients. Tumors were implanted over
the left lateral chest wall so that they could be easily
monitored and measured daily. Growth of tumors dur-
ing the first 3 weeks was similar between the WT and
SCD mice (Fig. 1a). From day 21 to 29, there was accel-
eration of tumor growth rate in both groups but the rate
of growth was markedly increased in the SCD group
compared to the WT group (Fig. 1a). Tumor volumes
and weights were both increased in the SCD compared
to WT mice at time of sacrifice (Fig. 1a, b, c). Body
weights of mice at the beginning and end of the protocol
were similar between the WT and SCD mice (24.93 ±
1.13 vs. 24.03 ± 0.79 grams on day 1; 25.46 ± 0.79 vs
25.74 ± 1.22 grams on day 29). Histological analyses showed
frequent microvascular occlusions in tumors from SCD
mice (Fig. 1d). Visible metastatic lung surface nodules were
present in 40 % of wild-type mice and 55 % of SCD mice at
the time of sacrifice. However, there was no significante (n = 10) and SCD mice (n = 10). b Representative image of tumor
d SCD mice at time of sacrifice. d Sickled erythrocytes within tumor
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exact test = 0.67).
Elevated HO-1 expression has been shown to pro-
mote the growth of melanoma [4]. Since HO-1 has also
been shown to be elevated in mice and human with
SCD [3, 14, 15], we analyzed HO-1 activity in melan-
oma tumor tissue taken from SCD and WT mice at the
time of sacrifice. HO-1 activity levels were higher in
melanoma tumors from SCD mice compared to WT
mice (1.12 ± 0.13 vs. 1.0 ± 0.08, respectively, p < 0.05).
To determine the causal role of HO-1 in promoting
tumor growth in mice with SCD, the tumor implant-
ation experiments were repeated with the addition of
the HO-1 inhibitor ZnPP. ZnPP (2.5 mg/kg) or vehicle
control was administered IP twice per week to WT and
SCD mice following tumor implantation. Consistent
with the initial study, tumor growth rate was acceleratedFig. 2 Accelerated tumor growth in SCD mice is prevented with suppressio
WT mice treated with ZnPP (n = 8) and SCD mice treated with ZnPP (n = 6
treated with ZnPP (n = 8) and SCD mice treated with ZnPP (n = 6). c Repres
from the 4 groups of mice, d Quantification of blood vessel density of tum
tumor weight and blood vessel density in SCD mice. f Correlation of blood
weight and HO-1 activity in SCD micein SCD mice treated with only vehicle control, however,
tumor growth rates in SCD mice treated with ZnPP were
similar to WT mice. ZnPP had no effect on growth rate of
tumors in WT mice (Fig. 2a). Tumor weights at sacrifice
confirmed the suppression of tumor growth in SCD mice
by ZnPP (Fig. 2b). To compare the HO-1 activity, the ac-
tivity of WT mice treated with vehicle is set as 1 and the
HO-1 activity in other groups was expressed as ratio to
control. HO-1 activity was elevated in SCD mice treated
with vehicle compared to WT mice treated with vehicle
(1.3 ± 0.25 vs. 1.0 ± 0.11, p < 0.05), however, HO-1 ac-
tivity was reduced in SCD mice treated with ZnPP
(0.65 ± 0.10 compared to WT mice treated with ve-
hicle, p <0.001 for comparison of SCD mice treated
with vehicle compared to SCD mice treated with
ZnPP). HO-1 activity was also reduced in WT mice
treated with ZnPP (0.8 ± 0.11, p = 0.02).n of HO-1. a Growth curves of WT mice (n = 10), SCD mice (n = 11),
). b Tumor weights of WT mice (n = 10), SCD mice (n = 11), WT mice
entative image of blood vessel (CD31) staining in tumor hot spots
ors from the 4 groups of mice. Scale bar =100 μm. e Correlation of
vessel density and HO-1 activity in SCD mice. g Correlation of tumor
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The pattern of late accelerated melanoma growth in
SCD mice suggested that enhanced tumor angiogenesis
in SCD mice may support accelerated tumor growth
[16]. Blood vessels in tumors were therefore quantitated
as previously described, [10] and found to be more fre-
quent in SCD tumors compared to WT tumors (Fig. 2c
and d). Increased vessel density was not observed in
SCD mice when mice were treated with ZnPP, indicating
HO-1 may be one of factors promoting angiogenesis in
SCD melanoma tumors (Fig. 2c and d). Correlation ana-
lysis between tumor weight, HO-1 activity, and vessel
quantitation in the individual mice revealed that tumor
size, HO-1 activity and vessel density are correlated in
SCD mice (Fig. 2e, f and g). However, tumor weight was
not correlated with HO-1 activity (R2 = 0.006, p = 0.84)
in WT mice.
Hemin is elevated in SCD and has been shown to in-
duce HO-1 [17]. To determine the effect of hemin on
HO-1 induction in endothelial cells, hemin was incu-
bated with endothelial cells in culture. Hemin induced
a dose dependent increase of HO-1 expression in endo-
thelial cells (Fig. 3a). To determine the angiogenic re-
sponse to hemin, hemin was incubated with isolated
aortic rings using an established aortic ring angiogen-
esis model [12]. Hemin increased the number of angio-
genic sprouts (Fig. 3b and c). This effect was blocked
with addition of ZnPP suggesting that hemin induced
angiogenesis via HO-1.Fig. 3 Hemin induces HO-1 expression in cultured endothelial cells and pr
bEend.3 cells treated with DMSO (control), 1 μM hemin or 5 μM hemin. b
1 μM hemin or 1 μM hemin with 2.5 μM ZnPP. c Representative images of
hemin with 2.5 μM ZnPP. Scale bar = 500 μmTo next determine the host angiogenic response under
endogenous conditions, matrigel was implanted in SCD
and WT mice. Seven days following matrigel implant-
ation, vessels were quantified and found to be increased
in SCD compared to WT mice (Fig. 4a and b). The in-
creased angiogenic response was blocked with ZnPP
treatment (Fig. 4a and b).
Discussion
The incidence, prevalence and outcomes of cancers in
patients with sickle cell disease remains ill-defined [18].
Many factors associated with SCD in humans may affect
the incidence and growth rates of cancer, including hy-
droxyurea treatment, chronic inflammation, transfusion-
related infections, focal ischemia due to sickling, and
chronic hemolysis. These factors may promote or impair
the growth of tumors. To our knowledge, the effect of
tumor growth in a host with SCD has not been described.
Murine models of SCD are available that mimic many of
the abnormalities observed in humans with SCD [19–21].
Because of the limited fertility of SCD mice and the com-
plexity involved in breeding heterozgyotes with back-
ground strain heterogeneity, bone marrow transplantation
was used. Bone marrow transplantation from a donor
sickle cell mouse to wild-type recipient can be used to
generate large numbers of age and sex-matched SCD mice
on a relatively homogenous genetic background. We have
previously used this method to study the effects of SCD
on vascular endpoints [3, 22]. The effects of SCD on theomotes angiogenesis from aortic rings. a HO-1 expression level in
Quantification of sprouts from aortic rings treated with DMSO (control),
sprouts from aortic rings treated with DMSO, 1 μM hemin or 1 μM
Fig. 4 SCD promotes angiogenesis in matrigel implants which is
suppressed via HO-1 suppression with ZnPP. a Representative images
of CD31 staining in matrigel plug sections. b Quantification of vessels
in matrigel plugs. Scale bar =100 μm
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protective responses depending on the vascular bed
and insult [3, 22]. Since tumor growth may be regulated
by angiogenesis [16], SCD could have major effects on
tumor growth since SCD may represent a proangio-
genic state [5]. Consistently, a previous study demon-
strated that injection of sickle cell red blood cells
accelerated 4T1 tumor growth in a murine model, an
effect reversible with ZnPP treatment [2].
The murine B16-F10 melanoma model has been ex-
tensively studied in mouse models [23] and tumor
growth has been shown to be affected by interventions
that impact angiogenesis [24]. Because of the relatively
rapid growth characteristics of the tumor, we tested the
effect of SCD on melanoma tumor growth. Growth rates
of the primary tumor were similar between SCD and
WT mice during the early growth phase following sub-
cutaneous injection. 3 weeks after tumor inoculation, a
rapid growth phase ensued possibly representing estab-
lishment of a supportive tumor vasculature. This rapid
growth phase was accelerated to a much greater degree
in SCD mice. Consistent with the hypothesis that this accel-
erated growth phase is promoted by tumor angiogenesis,tumors from SCD mice showed more vascularity compared
to WT mice. Products of hemolysis may trigger both dele-
terious and protective effects in SCD. For example, hemin
may induce acute chest syndrome in SCD [25] but may be
protective in other SCD-related complications [26]. For ex-
ample, administration of exogenous hemin has been shown
to further increase the cytoprotective enzyme, HO-1 [27].
Of relevance, human sickle cell blood has been shown to
induce HO-1 activity [28]. In this study, hemin induced
HO-1 in endothelial cells in vitro, and tumors from SCD
mice showed increased HO-1 activity in vivo. Since overex-
pression of HO-1 has been shown to promote melanoma
tumor growth [4], we tested the causal role of HO-1 in this
model by inhibiting HO-1 activity using ZnPP. HO-1 inhib-
ition not only blocked the accelerated tumor growth and
increased tumor vascularity but also blocked the effect of
hemin on endothelial sprouting from aortic rings as well as
the effect of SCD on angiogenic responses to matrigel
in vivo.
Study limitations
There was no effect of ZnPP on tumor growth in WT
mice suggesting to us that HO-1 is particularly relevant
in this melanoma model when upregulated, as in SCD.
HO-1 is expressed by B16-F10 melanoma cells as well as
several other host cell types [29–31]. We hypothesize
that HO1 activity is enhanced in SCD due to endothelial
cell or leukocyte production in response to products of
hemolysis, however we have not proven the relevant cell
type for effects we are observing in this model.
Whether the hemin mechanism is operative in vivo in
this tumor model will require additional study. Add-
itional inhibitors of HO-1, as well as antiangiogenic in-
terventions will also be helpful to confirm relevant
mediators involved in these observed effects.
Conclusions
In summary, SCD is associated with enhanced melan-
oma growth in a murine model that is mediated by en-
hanced HO-1 and angiogenesis. Therapies targeting
angiogenesis may be of particular use in SCD patients
with malignant tumors.
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